PD-1 belongs to a class of monoclonal antibodies that are promising treatments for achieving a cure for cancer. However, PD-1 monoclonal antibody can only be used as a more effective treatment in the middle and late stages of cancer, but there is no research data on cancer cure by immunotherapy for the time being. PD-1 can mainly block the binding between PD-1 and PD-L1 receptors and ligands between immune cells and tumor cells, which may have an inhibitory effect on immune T-lymphocytes and prevent or kill the effectivity of cancer. Monoclonal antibodies against PD-1 or PD-L1 can block the binding between the two, allowing the activation of immune cell activity, which then exerts cancer-killing effects. However, cures for intermediate and advanced cancers are relatively rare and the cure rate is very low. Suffering from cancer requires systemic comprehensive treatment, including surgical treatment, radiotherapy, chemotherapy, targeted therapy and other modalities. It prolongs the survival period and improves the quality of life.